Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Radiol Clin North Am. 2013 Sep;51(5):799-831. doi: 10.1016/j.rcl.2013.05.003. Epub 2013 Aug 1.

Role of positron emission tomography-computed tomography in gastrointestinal malignancies.

Author information

  • 1Department of Radiology, Brooke Army Medical Center, San Antonio Health Care System, 3851 Roger Brooke Drive, San Antonio, TX 78234, USA; Department of Radiology, Uniformed Services University of Health Sciences, 4301 Jones Bridge Rd, Bethesda, MD 20814, USA; Department of Radiology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA. Electronic address: kevin.banks@amedd.army.mil.

Abstract

Positron emission tomography (PET) has proved itself to be valuable in the evaluation of patients with a wide array of gastrointestinal (GI) malignancies. Subsequent development of fusion imaging with PET and computed tomography (PET-CT) scanners has significantly advanced the capabilities of imaging by combining the functional data of the(18)F-labeled glucose analogue fluorodeoxyglucose (FDG) with the conventional anatomic data provided by CT. This article reviews the evolving role of FDG PET-CT imaging in the initial assessment and monitoring of GI tumors. Specific applications are discussed, and normal variants and benign findings frequently encountered during PET-CT of the GI tract are reviewed.

Published by Elsevier Inc.

KEYWORDS:

(18)F-Fluorodeoxyglucose; Gastrointestinal malignancies; Neoadjuvant therapy; Positron emission tomography–computed tomography

PMID:
24010907
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk